International Health News (Health, Nutrition, Medicine)

Your on-line source of concise, authoritative health, nutrition and medicine news




Number 131
NOVEMBER 2002
11th Year


Download Acrobat Reader
View in .pdf Format
Download Acrobat Reader


EDITORIAL

The mission of the US Food and Drug Administration (FDA) is to "protect the public health by ensuring that human drugs are safe and effective". There is increasing evidence that this mission is being ignored in favour of supporting Big Pharma at all costs. One major reason for this is no doubt that the FDA now receives about half its annual operating budget from pharmaceutical companies. Another reason may well be that the FDA has been infiltrated by political appointees and supporters of Big Pharma. In any case, it is increasingly becoming a "buyer beware" situation when it comes to drugs. A case in point is the launching, withdrawal, and relaunching of the IBS drug alosetron, which caused at least 7 deaths and 143 admissions to hospital.

The promotional tactics of Big Pharma are also coming under increasing scrutiny. A recent study claimed that the ACE inhibitor ramipril reduced non-fatal stroke risk by 32%. A more sober evaluation reveals that the absolute risk reduction per year is more like 0.2% and that the cost of preventing a single stroke would be about $US14,000 – 36,000 per year. Much less impressive!

What it all means is that pronouncements made by Big Pharma and the FDA must be taken with an increasingly large grain of salt.

On a more uplifting note. With this issue we begin a 3-part series of articles dealing with the association between fats and cardiovascular and other diseases. The articles are written by our very first guest author Dr. William Ware, Emeritus Professor of Chemistry, University of Western Ontario, London, Ontario, Canada. They provide an up-to-date review of the relationship between fats and health and disease and debunk many myths that are keeping people from consuming an optimum diet.

Enjoy!

Yours in health,
Hans Larsen, Editor



ABSTRACTS

OXIDATIVE STRESS: CAUSES AND PREVENTION

BERKELEY, CALIFORNIA. Oxidative stress occurs when the body's antioxidant defenses are overwhelmed by free radicals generated whether internally or by environmental exposure. It can damage DNA, proteins and lipids (fats) and has been linked to several diseases and disorders. A group of American researchers has just released the results of a study aimed at measuring the extent of oxidative stress found in a representative sample of the US population.
The study involved 298 healthy adults between the ages of 19 and 78 years who completed food frequency questionnaires and provided blood samples. The researchers analyzed the samples for two markers of oxidative stress; malondialdehyde (MDA) and F2-isoprostanes (Iso-P). MDA is a decomposition product of polyunsaturated fatty acids while Iso-P are eicosanoids produced by oxidation of metabolites of arachidonic acid. There was a clear correlation between MDA and Iso-P levels and gender with women having significantly higher levels than men. Smokers had significantly higher levels of MDA while obese individuals had significantly higher levels of Iso-P. A high intake of fruits, a high blood level of ascorbic acid (vitamin C), and a high blood level of beta-carotene were all associated with lower levels of both markers indicating that fruits, beta-carotene, and especially vitamin C are highly protective against oxidative stress. There were no correlations between markers of oxidative stress and age, alcohol consumption, fat intake, meat consumption, and vitamin E (alpha-tocopherol) level. A high C-reactive protein level was, however, associated with a high MDA level and a high level of gamma-tocopherol was, somewhat surprisingly, associated with higher levels of both MDA and Iso-P.
The researchers conclude that high blood levels of ascorbic acid may be protective against oxidative stress, particularly DNA damage and urge that all future epidemiologic studies include measurements of blood levels of ascorbic acid and, at least, one of the biomarkers for oxidative stress.
Block, Gladys, et al. Factors associated with oxidative stress in human populations. American Journal of Epidemiology, Vol. 156, August 1, 2002, pp. 274-85

OATMEAL PORRIDGE IS BETTER FOR YOU

FORT COLLINS, COLORADO. A low-fat, high-fiber diet is often recommended for reducing cholesterol levels and lowering heart disease risk. Rarely is it specified what kind of dietary fiber should be eaten in order to obtain the benefits. Researchers at Colorado State University now report that soluble fiber (from oat products) is far more effective in reducing critical cholesterol components than is insoluble fiber (from wheat products). Their clinical trial involved 36 overweight men between the ages of 50 and 75 years who were randomized to consume two large servings per day of either oat cereal or wheat cereal for a 12-week period.
The researchers found that men assigned to the oat cereal group showed a very significant drop (-17.3 per cent) in the level of small, dense LDL particles while wheat cereal consumers saw a marked increase (+60.4 per cent). Small, dense LDL cholesterol particles are believed to be much more likely to cause atherosclerosis than are larger, less-dense LDL particles. The LDL/HDL cholesterol ratio showed a beneficial drop (-6.3 per cent) in the oat group compared to an increase (+14.2 per cent) in the wheat group. A similar trend was noted for triglyceride level that dropped by 6.6 per cent in the oat group and increased by 22 per cent in the wheat group.
The researchers conclude that oat cereal consumption is associated with beneficial cholesterol changes that may contribute to the cardioprotective effect of oat fiber. NOTE: This study was partially funded by The Quaker Oats Company.
Davy, Brenda M., et al. High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL- cholesterol subclass and particle numbers in middle-aged and older men. American Journal of Clinical Nutrition, Vol. 76, August 2002, pp. 351-58

TESTING FOR HYPOTHYROIDISM

BRISTOL, UNITED KINGDOM. Hypothyroidism (an underactive thyroid gland) is diagnosed through the measurement of three hormones, T3 (triiodothyronine), T4 (thyroxine), and TSH (thyroid-stimulating hormone or thyrotropin). If levels of T3 and T4 are low or normal and the level of TSH is abnormally high then hypothyroidism is deemed to be present. The reference range for TSH is 0.2 – 5.5 mU/L. This range was arrived at by measuring TSH levels in a large group of seemingly healthy people. Several researchers have recently questioned this approach. They point out that undiagnosed, subclinical hypothyroidism may be present in up to 40 per cent of women. This obviously could have skewed the results since these women would have been considered healthy even though they actually had low-grade hypothyroidism.
A group of British researchers now suggest that the reference range for TSH may be too wide. They point out that when a group of individuals with no history of thyroid disease and no antibodies against thyroid peroxidase was tested their TSH values fell within a much narrower range of 0.48 – 3.60 mU/L. Other studies have shown that TSH values above 1.9 mU/L are associated with thyroid peroxidase antibody positivity indicating abnormal pathology in the thyroid. There is also evidence that individuals with TSH values greater than 2.0 mU/L have an increased risk of developing clinical hypothyroidism over the next 20 years. The researchers believe that a TSH range of 0.5 – 3.5 mU/L rather than 0.2 – 5.5 mU/L should be considered the norm, but point out that there is emerging epidemiological data suggesting that a TSH level above 2.0 mU/L may be associated with adverse effects.
Dayan, Colin M., et al. Whose normal thyroid is better – yours or mine? The Lancet, Vol. 360, August 3, 2002, pp. 353-54 (commentary)

ACCURACY OF EAR TEMPERATURE QUESTIONED

LIVERPOOL, UNITED KINGDOM. A precise and accurate measurement of body core temperature is essential in order to determine the presence of fever. Rectal temperature has traditionally been considered to be the best approximation of core temperature and is still the gold standard when an accurate measurement is required. Taking a rectal temperature is, however, uncomfortable and time-consuming so the idea of measuring core temperature by infrared ear thermometry has gained wide acceptance. It is estimated that 64 per cent of pediatricians and 65 per cent of family physicians in the USA now use an infrared ear thermometer to measure temperature with the practice being particularly widespread when it comes to children.
Medical researchers at the University of Liverpool have just completed a review of 31 studies (involving 4441 individuals [75 per cent children]) aimed at evaluating the correlation between infrared ear temperature and standard rectal temperature. The infrared ear thermometers all had an electronic feature that adjusted the actual measurement to correspond to a rectal temperature. The researchers found that the rectal temperature calculated from infrared ear thermometry was on average 0.29 degrees C (0.46 degrees F) lower than the actual rectal temperature. However, the extent of discrepancy was quite wide. For example, for a true rectal temperature of 38 degrees C, the "rectal temperature" measured at the ear could be anywhere between 37.0 and 39.2 degrees C. The researchers conclude that in children infrared ear thermometry cannot be used as an accurate approximation of rectal temperature.
Craig, Jean V., et al. Infrared ear thermometry compared with rectal thermometry in children: a systematic review. The Lancet, Vol. 360, August 24, 2002, pp. 603-09
Akinyinka, O.O. Infrared ear thermometry versus rectal thermometry in children. The Lancet, Vol. 360, August 24, 2002, p. 584 (commentary)

VITAMIN E PROTECTS AGAINST ALZHEIMER'S DISEASE

CHICAGO, ILLINOIS. There is growing evidence that oxidative stress is a major factor in the development of Alzheimer's disease (AD). It is believed that accumulated damage to DNA and lipid membranes arising from attacks by free radicals and reactive oxygen species disrupt the normal functioning of cells and leads to neuronal death. Dietary antioxidants such as vitamin C, vitamin E and beta-carotene are highly effective in preventing oxidative stress and might thus help protect against the development of AD.
A team of American researchers has just released the results of a study aimed at determining whether older people with a high intake of dietary antioxidants are less likely to develop AD than are people with a lower intake. The study involved 815 people aged 65 years or older who were deemed to be free of AD when they entered the study. After an average follow-up of 3.9 years 131 of the participants had developed AD as ascertained through a 2.5-hour evaluation by a neurologist and support staff. The participants' intake of vitamin C, vitamin E and beta-carotene was determined via a food frequency questionnaire completed 1.7 years after baseline or about 2.3 years before the evaluation for AD.
The researchers found that participants with a high intake of vitamin E from food had a 67 per cent lower risk of developing AD than did people with a low intake. This correlation only held true in participants who were negative for the APOE epsilon4 allele (a known genetic risk factor for AD). Higher intakes of vitamin C and beta-carotene had no statistically significant effect on the risk of AD and there was no indication that supplementing with antioxidant vitamins, including vitamin E, was associated with a reduced risk. There was, however, a trend for vitamin E (both from food and supplements) to prevent a decline in cognitive function over the study period.
Morris, Martha Clare, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. Journal of the American Medical Association, Vol. 287, June 26, 2002, pp. 3230-37

VITAMIN B12 DEFICIENCY EASY TO AVOID

KINGSTON, CANADA. Many older people suffer from a deficiency of vitamin B12 (cobalamin). A low intake of animal protein, the use of medications to reduce stomach acid, a Helicobacter pylori infection, an inflammation of the stomach lining, and problems with the pancreas can all contribute to the development of a deficiency. Medical researchers at Queen's University now report that daily supplementation with a multivitamin containing 2.6 – 37.5 micrograms of vitamin B12 is enough to prevent a cobalamin deficiency in most older healthy people. Their study involved 242 active, relatively healthy men and women aged 65 years or older. Sixty-six (27.3 per cent) of the volunteers had been taking a daily multivitamin containing 2.6 – 37.5 micrograms of vitamin B12 for at least six months.
All volunteers had blood samples drawn for the measurement of cobalamin level as well as the levels of the related metabolites methylmalonic acid (MMA), homocysteine (HCYS) and methylcitric acid (MCTR). Thirty- seven (15.3 per cent) of the 242 participants were deficient in cobalamin (level below 165 pmol/L). Of these 37 only 2 were taking multivitamins. An elevated level of MMA was found in 53 participants of whom 46 (87 per cent) were not taking multivitamins. An elevated level of homocysteine was found in 17 participants of whom 16 were not supplementing. The researchers conclude that oral supplementation with 25 micrograms/day or higher may be sufficient to prevent vitamin B12 deficiency in a large proportion of older people. They caution though that their findings cannot be extrapolated to frail or sick old people who may require larger doses to avoid deficiency.
Garcia, Angela, et al. Is low-dose oral cobalamin enough to normalize cobalamin function in older people? Journal of the American Geriatrics Society, Vol. 50, August 2002, pp. 1401-04

RESULTS OF RAMIPRIL TRIAL QUESTIONED

LONDON, UNITED KINGDOM. A major clinical trial recently concluded that the ACE inhibitor ramipril (Altace) is highly effective in preventing stroke. The trial involved 9296 patients with vascular disease or diabetes. At the end of the study the researchers concluded that ramipril lowers the risk of non-fatal stroke by 32 per cent and the risk of fatal stroke by 61 per cent. What was not highlighted in the report was that the non-fatal stroke rate in the placebo group was 3.9 per cent or about 0.9 per cent a year compared with 3.0 per cent or 0.7 per cent a year in the ramipril group, i.e. an absolute difference of about 0.2 per cent in the annual incidence of non-fatal stroke. The difference in the annual incidence of fatal stroke was even less impressive at 0.13 per cent.
The presentation of the data for ramipril, i.e. claiming reductions of 32 per cent and 61 per cent in stroke risk, is somewhat similar to the presentation used in the promotion of warfarin (Coumadin). Here a relative risk reduction of 64 per cent is claimed even though the absolute risk reduction when taking warfarin is only about 1.7 per cent a year.
Several medical doctors have expressed concern about the study and point out that the benefits of ramipril treatment have been vastly overstated by the use of relative rather than absolute risk reduction percentages. One doctor points out that the cost of preventing one single stroke with ramipril over a 4.5-year period would be somewhere in the range of US$ 64,000 – 160,000. NOTE: The original ramipril study was sponsored by several pharmaceutical companies.
Bosch, Jackie, et al. Use of ramipril in preventing stroke: double blind randomised trial. British Medical Journal, Vol. 324, March 23, 2002, pp. 1-5
Preventing stroke with ramipril. British Medical Journal, Vol. 325, August 24, 2002, pp. 439-41 (letters to the editor)

NIACIN HELPS DIABETICS

DALLAS, TEXAS. Patients with type 2 diabetes have a 2- to 4-fold excess risk of developing cardiovascular disease. The main reason for this is that their mechanism for suppressing fatty acid release from adipose (fat) tissue after food intake is impaired. This leads to high blood levels of triglycerides and low-density lipoprotein (LDL) cholesterol and low levels of beneficial high-density lipoprotein (HDL) cholesterol. All of these changes are highly detrimental and increase the risk of atherosclerosis.
It has long been known that niacin (vitamin B3) increases HDL cholesterol and decreases LDL cholesterol and triglycerides. However, taking crystalline niacin causes highly uncomfortable flushing and time-release formulations have been associated with liver toxicity. There has also been concern that niacin might increase fasting blood glucose levels.
Members of the Diabetes Multicenter Research Group have just released the results of a major clinical trial designed to test the efficacy and safety of a new extended-release (ER) niacin (Niaspan by Kos Pharmaceuticals, Miami, FL). The double-blind, placebo-controlled trial was carried out in 19 American hospitals and clinics and involved 148 patients with type 2 diabetes. The patients were randomized to receive a placebo, 1000 mg/day of Niaspan or 1500 mg/day of Niaspan for 16 weeks.
At the end of the 16 weeks the HDL cholesterol levels in the 1000 mg/day group had increased by about 16 per cent and the HDL level in the 1500 mg/day group had increased by 23 per cent. At the same time triglyceride levels in the 1000 mg/day group and the 1500 mg/day group had decreased by about 17 per cent (not statistically significant) and 32 per cent (statistically significant) respectively. The level of LDL cholesterol increased slightly in both the placebo and 1000 mg/day groups, but decreased by 7 per cent in the 1500 mg/day group. The niacin regimens were well tolerated, had no significant adverse effects, and did not affect glucose control significantly. The researchers conclude that low doses (1000 – 1500 mg/day) of ER niacin are effective and safe for the management of dyslipidemia (abnormally high fat levels in the blood stream) associated with type 2 diabetes. NOTE: This study was partially funded by Kos Pharmaceuticals.
Grundy, Scott M., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Archives of Internal Medicine, Vol. 162, July 22, 2002, pp. 1568- 76



NEWSBRIEFS

Who is watching the watchdog?
The mission of the US Food and Drug Administration (FDA) is to "protect the public health by ensuring that human drugs are safe and effective". There is increasing evidence that this mission is being replaced by the goal of supporting the pharmaceutical industry (Big Pharma) at all costs. The recent debacle surrounding the irritable bowel syndrome (IBS) drug alosetron is a case in point. This drug, released in February 2000, was hailed as the definitive answer to IBS. By November 2000 the drug had resulted in 3 deaths, 10 surgical interventions, and 44 admissions to hospitals. It was withdrawn from the market shortly after. However, following continued pressure from pharmaceutical companies and self-help groups sponsored by Big Pharma the FDA gave the go ahead in June 2002 to use the drug in selected cases. Experts familiar with the drug expect the death toll and rate of hospital admissions to rise among users of the drug. Paul Stolley, the senior consultant who first warned about alosetron has resigned from the FDA. He wonders if the FDA is really watching out for the public's best interest and says, "It [the FDA] is confused and frightened. It's getting its money from industry now and it's afraid to offend these companies. And remember Big Pharma was one of the biggest contributors to the Bush campaign".
British Medical Journal, Vol. 325, September 14, 2002, pp. 555-56, 592-95

US government stockpiles potassium iodide
In the wake of September 11th the US government has been stockpiling potassium iodide tablets and is now offering them to states housing nuclear power plants. A nuclear accident is likely to cause the release of radioactive iodine, which, if it gets into the thyroid gland, can result in thyroid cancer. If potassium iodide tablets are taken soon enough after the accident they will saturate the thyroid with iodine thus leaving no room for the radioactive iodine. So far only 16 states have taken up the offer.
British Medical Journal, Vol. 325, July 20, 2002, p. 119

Mid-air emergencies
Flying can be very stressful and it is estimated that 500 – 1000 airline passengers die every year in mid-air from heart attacks, strokes or pulmonary problems. This compares to a toll of 658 people who died in airplane crashes in 2000. A New Scientist investigation recently concluded that many lives could be saved if airlines would take simple steps, such as carrying a defibrillator onboard, to improve the quality of their medical emergency kits. Technology is now available for measuring the vital signs of an ill passenger, transmitting them to a ground-based medical center, and receiving immediate first aid instructions from a specialist. So far, only one of the world's 278 commercial airlines has chosen to invest in this new technology.
New Scientist, August 31, 2002, pp. 10-11

Electric fields play a key role in healing
Researchers at the University of Aberdeen have found that the body's internal electric field plays a crucial role in the healing of damaged cells and tissue. Dr. Colin McCaig and his team studied the healing of damaged rat corneas. In an undamaged cornea positively charged ions are continuously pumped into the cornea while negatively charged ions are pushed out. This creates an electrical potential of 40 millivolts. In a damaged cornea this electric field disappears. However, by artificially inducing an electric field healing is speeded up significantly. Dr. McCaig believes that the field attracts positively charged proteins or lipids in the membranes of cells. An American team is currently working on the idea of speeding up the healing of spinal cord injuries by applying an external electrical field.
New Scientist, September 28, 2002, p. 15



RESEARCH REPORT

Dietary Fat and Coronary Heart Disease. Is There a Connection?

Part I

by William R. Ware, Ph.D.

Emeritus Professor of Chemistry, University of Western Ontario, London, Ontario, Canada


The belief among the general public that fat is bad is almost universal. All fats, the saturated, monounsaturated, polyunsaturated and trans-fats are lumped together and regarded with a jaundiced view if not outright condemnation. According to the conventional wisdom, fat is implicated in heart disease, stroke, cancer, obesity, and diabetes. However, not all nutritional scientists and experts in the etiology of heart disease and cancer agree with this view of fat. In fact, public opinion appears to be about five to ten years behind the results of modern science in this regard.

The problem of the relationship between dietary fat and health is exceedingly complex. Since the principal health question regarding fat relates to its association with the risk of coronary heart disease (CHD), this becomes the central issue that must be examined. Not only are there several distinct types of fat, but there are a number of different consumers, i.e., old, young and in between, men and women, pre- and postmenopausal women, individuals with the so-called metabolic syndrome or Syndrome X, the obese and the overweight, those with normal and those with abnormal blood lipids (the several cholesterol fractions and triglycerides), diabetics, individuals who have had a heart attack and individuals who are thought to be free of all coronary heart disease, smokers and non-smokers, etc. Most studies look at only a few sub-sets of this general population. Since fat consumption alters cholesterol levels, the fat-heart disease question must also involve a consideration of the relationship between fat consumption and cholesterol on the one hand, and cholesterol and heart disease on the other. Thus the subject is far from simple.

The history of the anti-fat movement will be reviewed first, followed by an examination of what modern nutritional epidemiology and nutritional science has revealed about the merits and risks of dietary fat, especially in the context of coronary heart disease. Then we will discuss low-fat and high-fat diets with these results in mind.

THE ANTI-FAT MOVEMENT

In the last twenty-five to thirty years, fat has gone from being taken for granted as a normal constituent of Western diets to being branded public enemy number one. This change came about through the efforts of the US Government, mainly the USDA, and various groups such as the American Heart Association, the National Academy of Science, and the American Dietetics Association. The anti-fat movement was also greatly assisted by the medical profession and the media, both of whom were active in spreading the word. The battle cry--fat causes heart disease, strokes and cancer--was, as might be expected, very effective. The food industry picked up on this movement very early and an ever-increasing stream of low-fat, lite, low- cholesterol, and zero-fat products have appeared on the shelves of the supermarkets. Fat substitutes have become popular--they taste like fat but are not digestible. Books on low-fat diets have appeared by the dozens. An almost zero-fat diet was claimed to reverse heart disease, which the general public has been lead to believe is caused by dietary fat and cholesterol particles plugging up the coronary arteries (unfortunately, it is not that simple). The USDA came out with its famous food pyramid, which basically favors a high-carbohydrate and low-fat diet. Today the notion that fat is bad is securely established in the minds of the general public. In fact, the movement has many of the attributes of an organized religion. It is therefore quite interesting that the lumping of all fat into one category and labeling it as bad has virtually no basis in modern scientific studies, and the elimination of some fats from the diet can have very serious health consequences. Gary Taubs, in his recent feature article in the journal Science (1) called it "The Soft Science of Dietary Fat." His article contains an excellent review of the anti-fat movement.

A problem with the early studies that led to the condemnation of fat was that the various fats were lumped together as simply fat, without regard for the fact that there were thought to be good fats and bad fats. The need for and actions of the good fats were, to some extent, recognized and understood even at the start of the anti-fat campaign, and this was the basis of the opposition from a number of scientists. It turned out that their concerns were ignored. Today it is absolutely clear that any discussion or study concerning fats and health must deal with the individual fats, that is, the saturated fats, the monounsaturated fats, the polyunsaturated fats (with special attention to the omega-3 and omega-6 fats), and the trans-fats, which are mostly man-made (2). This obviously complicates matters quite considerably. In fact, when the decision was made to condemn all fats, part of the motivation was the view that the general public was not able to deal with these complexities, which was probably correct. A decrease in consumption of the good fats was considered the price that had to be paid to decrease the consumption of what were viewed as the bad fats. The molders of public opinion considered that on balance there would be benefit, and they would not listen to those who disagreed and pointed out the risks. Also, how bad the trans-fats were was not fully appreciated in the early days of the low-fat movement, when part of the gospel was to replace butter with margarine, which was high in trans-fat. More on this later.

Another problem with the early studies that led to the condemnation of all fat was that, by modern standards, they were rather crude. The science of nutritional epidemiology has changed significantly during the last twenty years, with the result that study design has vastly improved, statistical power increased, and the ability to correct for confounding factors has reached a very high level (3). An example of the confounding factor problem is as follows. Let's say a study finds that heavy drinking of alcohol is positively associated with lung cancer. But since heavy drinkers also tend to be smokers, frequently heavy smokers, the data must be corrected for the known risk of lung cancer associated with smoking. Otherwise the observed association of drinking with lung cancer is meaningless. Studies of dietary fat and health are confounded by numerous factors associated with both lifestyle and other nutritional factors. Early studies by and large failed to deal effectively with this problem.

Finally, in the period when the early studies were being performed, little was known about the relationship between the various blood lipid fractions such as HDL, LDL, and the triglycerides, and the risk of cardiovascular disease. Only total cholesterol was measured. At present, there is considerable information on the relationship of the various lipid fractions to CHD risk, and this continues to be an active area of research.

Today, the early studies of the relationship between fat and health are regarded by many nutritional epidemiologists as mainly of historical interest, although these studies are still quoted by proponents of the "all fat is bad" religion as they struggle to maintain their viewpoint. In what follows, the subject of dietary fat will be explored in some detail, with special emphasis on potential health problems associated with low-fat diets. The questions that need to be addressed are as follows:

  • Which fats, if any, are bad, which fats are good? What is the actual evidence?
  • Do fats really cause heart disease and cancer?
  • Are there dangers associated with low and very low fat diets?
  • On the basis of modern nutritional epidemiology, what are the recommendations as regards optimum balance of the various types of fat, carbohydrate and protein in the diet if the goal is to remain healthy?

FAT CONSUMPTION AND HEART DISEASE

There are three types of study that are of importance in this context. One involves following large groups of individuals, the so-called cohorts, using food frequency questionnaires and in some cases interviews. Subjects are followed for a number of years, and the participants in any given study may number in the thousands to tens of thousands. Associations are sought between diet and the incidence of one or more health problems that occur at a later date (the prospective, cohort study). The second type of study involves an intervention. In the present context, the two common ones are (a) reducing the total intake of fat in general, and (b) replacing saturated fat with unsaturated fat, keeping the total fat calories approximately constant. In connection with the diet-heart hypothesis, the investigators then look for changes in the incidence of events related to heart disease, such as a survived or fatal heart attack. From such studies, one can determine if there is an association between fat intake and the incidence of adverse coronary events. A third type of study, called the case-control study, involves recruiting both a group of individuals with a specific problem or problems and a control group presumed free of the problem or problems. Factors are then sought that are present in the group with problems and absent in the controls.

In connection with the questions of whether or not scientific studies support the hypothesis that there is an association between adverse heart events and the consumption of either saturated or polyunsaturated fat, Willett (3) has reviewed 21 prospective cohort studies involving over a quarter-million participants. Four of the nineteen studies supported the hypotheses that saturated fat was bad, 10/19 showed no significant association, and the balance provided insufficient information. In connection with the hypotheses that polyunsaturated fat was beneficial, 4/19 supported this hypothesis, 9/19 showed no association, and the balance provided insufficient information. There are two other similar reviews in the recent literature (4,5). One essentially agrees with the Willett analysis, the other finds a slight suggestion that saturated fat may have an adverse association, but the association is weak. There is a small but significant variation in the studies included in these two last mentioned reviews, but the general picture is clear. If saturated fat were tried before a judge and jury on the basis of this evidence, it would no doubt be acquitted! The evidence is simply inconclusive.

Nine dietary intervention studies have also been reviewed by Hu and coworkers at Harvard (6). In the studies reviewed, groups of individuals were randomly assigned to an intervention or control group, and the incidence of events in the intervention group was compared with the number found in the control group. Two of the studies involved presumably healthy individuals, and seven involved patients who had experienced a heart attack. Two of the studies involved reducing total fat. One found a benefit (reduced adverse coronary events), the other found none. In both cases the changes were very small. Of the seven other studies included in the review, in six the intervention involved decreasing saturated fat and increasing unsaturated fat. In one study, the intervention involved adopting a Mediterranean type diet augmented with alpha- linolenic acid, one of the omega-3 essential fatty acids. Six of the seven studies found a significant benefit whereas one found none.

The study that found the largest decrease in adverse coronary events was the one that involved switching to a Mediterranean diet. In this study the changes in total cholesterol were also tabulated. The change in the incidence of adverse coronary events failed completely to correlate with the change in the serum cholesterol. If the data are plotted, one obtains a scatter diagram with no visible trend or correlation. In the study where there was the largest decrease in adverse coronary events (73%), there was no on-average change in the serum cholesterol. Note that seven of the nine studies involved heart attack patients--so- called secondary prevention. Also note that in the studies where saturated fat was replaced with unsaturated fat, two variables are being simultaneously changed. Also, only two of the studies where saturated fat was replaced by unsaturated fat involved healthy individuals (primary prevention), and one of these found no effect. These studies nevertheless are universally viewed as providing convincing evidence that the action of replacing saturated fat with unsaturated fat is a beneficial move in the context of heart disease, especially preexisting heart disease. In fact, it is hard to argue with the overall benefit observed, which was quite large. However, such studies fail to prove that saturated fat is bad, since that question was not studied in isolation. The prospective cohort studies mentioned earlier attempted to pull out saturated fat as an independent variable but failed to provide any conclusive or consistent evidence that it was bad. Conclusive evidence that polyunsaturated fat was good was also not obtained in these cohort studies. The advice to decrease saturated fat and increase polyunsaturated fat is now incorporated in most modern recommendations as a presumably beneficial dietary modification.

It seems clear that on the basis of the above studies, one cannot conclude that the consumption of saturated fat has been proven to be bad in the context of heart disease. In fact, it would appear close to neutral. If it is indeed dangerous to the heart, the risk is too small to stand out even in a large number of studies. After all, the prospective cohort studies discussed above involved over a quarter-million subjects! The fact that this point of view is at variance with the older studies has been explained by the failure to take into account confounding factors. Also, selection of only data favorable to the fat-heart disease hypothesis appears to have taken place. In the most notorious case, a comparison of the incidence of heart disease, as a function of fat consumption for a group of different nations, led to a remarkable, straight-line correlation where, in fact, when all the data available at the time are used, a scatter plot with no correlation is obtained (7). Yet this study was for years the basis of the belief that fat consumption caused heart disease and is still quoted by those who adhere faithfully to this dogma.

TRANS-FATTY ACIDS

Polyunsaturated fats, as a class, include the so-called trans-fats. Most of the trans-fats encountered in the modern diet are man-made by the partial hydrogenation of polyunsaturated fats using high temperature and a metal catalyst. While the question of whether or not saturated fat is bad will no doubt continue to be debated, there appears no question whatsoever that trans-fats are bad, in fact really bad. Yet they permeate the modern diet. Part of the motivation for their creation was vastly extended shelf life, since natural unsaturated fats oxidize easily and thus become rancid. Also, this was a way to make liquid fat into solid fat, such as Crisco and stick margarine. The body treats trans-fats like real fats, and, among other things, incorporates them into the cellular lipid bilayer. They are found in fried foods such as French fries, baked goods, and in many prepared foods. There has been a lot of research on the problems caused by the consumption and metabolism of trans-fats. For example (2):

  • Trans-fatty acids lower HDL in a dose response fashion, i.e. the more you eat, the lower it gets (the wrong direction for the so-called good cholesterol).
  • Trans-fatty acids increase LDL (the so-called bad blood lipid). >li> Trans-fatty acids raise lipoprotein(a), which is regarded as undesirable
  • Trans-fatty acids raise total cholesterol in the blood by as much as 20 to 30 mg/dL.
  • Trans-fatty acids decrease the levels of testosterone in males and increase the number of abnormal sperm.
  • Trans-fatty acids inhibit the function of a number of essential enzymes in the body associated with the chemistry of omega-3 and omega-6 fatty acids.
  • Trans-fatty acids interfere with the action of enzymes that metabolize toxic chemicals.
  • Trans-fatty acids decrease the response of cells to insulin. They hamper the proper function of the insulin receptors by changing the fluidity of the lipid bilayer and other cellular membranes. Thus they may contribute to insulin resistance.

This is a horrible report card for something that today is a major constituent of the typical North American diet. It is estimated that for a typical teenage diet with 3000 calories and 35% from fat, that 40% of the fat calories are from trans-fats. It may be even higher. Trans-fats totally permeate the processed food production. Until the trans-fat content is included as a part of the label on all processed foods, all one can do is look for the words partially hydrogenated and avoid all products that contain such ingredients. Individuals wishing to avoid trans-fats should avoid all commercial baked goods, reject margarine totally (unless it is the new trans-fat free product) and avoid all deep fried foods as well unless they are deep fried at home, using fresh unsaturated oils at a minimum temperature to accomplish the cooking. Some scientists who have studied the trans-fat phenomenon in detail consider it to be potentially one of the major health problems of the 21st century.



References

  1. Taubs, Gary. The Soft Science of Dietary Fat. Science, Vol. 291, No. 5513, March 30, 2001, pp.2536-45.
  2. Eing, Mary. Know Your Fats. 2000, Bethesda Press
  3. Willett, Walter. Nutritional Epidemiology. 1998, Oxford University Press.
  4. Ravnskov, Uffe. The Questionable Role of Saturated and Polyunsaturated Fatty Acids in Cardiovascular Disease. Journal of Clinical Epidemiology, Vol. 51, No. 6, June, 2002, pp. 443-60.
  5. Hooper, Lee, et al. Dietary Fat Intake and Prevention of Cardiovascular Disease: Systematic Review. British Medical Journal, Vol. 322, No. 7289, March 31, 2001, pp. 757-63.
  6. Hu, Frank, et al. Types of Dietary Fat and Risk of Coronary Heart Disease: A Critical Review. Journal of the American College of Nutrition, Vol. 20, No. 1, February 2001, pp. 5-19.
  7. Ravnskov, Uffe. The Cholesterol Myths. 2000, New Trends Publishing.



Return to ENTRANCE
Message to the Editor


International Health News is published monthly by Hans R. Larsen MSc ChE
1320 Point Street, Victoria, BC, Canada V8S 1A5
Phone: (250) 384-2524
E-mail: health@pinc.com
URL: http://www.yourhealthbase.com
ISSN 1203-1933.....Copyright © 2002 by Hans R. Larsen

International Health News does not provide medical advice. Do not attempt self- diagnosis or self-medication based on our reports. Please consult your health-care provider if you wish to follow up on the information presented.